Edition:
India

AB Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

4.58EUR
18 Apr 2019
Change (% chg)

€-0.32 (-6.63%)
Prev Close
€4.91
Open
€5.00
Day's High
€5.05
Day's Low
€4.58
Volume
128,079
Avg. Vol
55,879
52-wk High
€8.27
52-wk Low
€3.10

Latest Key Developments (Source: Significant Developments)

Ab Science Says IDMC Recommends Continuation Of masitinib Phase 3 Study With No Requirement To Increase Sample Size
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - AB SCIENCE SA ::REG-AB SCIENCE ANNOUNCES THAT BASED ON INTERIM ANALYSIS, IDMC RECOMMENDED THE CONTINUATION OF THE MASITINIB PHASE 3 STUDY IN PROGRESSIVE MULTIPLE SCLEROSIS WITH NO REQUIREMENT TO INCREASE THE SAMPLE SIZE.‍FINAL RESULTS OF STUDY ARE EXPECTED IN Q2 2019​.‍IDMC DID NOT REPORT ANY SAFETY CONCERN WITH MASITINIB IN STUDY POPULATION​.  Full Article

AB Science net loss narrows to 13.5 million euros
Thursday, 31 Aug 2017 

Aug 31 (Reuters) - AB SCIENCE SA ::NET LOSS OF 13.5MEUR IN FIRST HALF OF 2017, A DECREASE OF 8.4% AS COMPARED WITH FIRST HALF OF 2016 (14.7MEUR ).CASH POSITION OF 49.3MEUR AS OF 30 JUNE 2017, PLUS 6.9MEUR OF 2016 TAX CREDIT TO BE REIMBURSED BY PUBLIC FINANCE DEPARTMENT.PHASE 2/3 STUDY AB10015 OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) MET ITS PRE-SPECIFIED PRIMARY ENDPOINT, WHICH CONFIRMS INTERIM ANALYSIS.COMPANY TURNOVER AMOUNTS TO 842 K€ FOR THE FIRST HALF OF 2017, AS COMPARED WITH 772 K€ ONE YEAR EARLIER.OPERATING LOSS AS AT 30 JUNE 2017 AMOUNTED TO 13,709 K€ AS COMPARED WITH 16,099 K€ AS AT 30 JUNE 2016.  Full Article

AB Science announces issuance of a new european patent
Wednesday, 12 Jul 2017 

July 12 (Reuters) - AB SCIENCE SA ::REG-AB SCIENCE ANNOUNCES ISSUANCE OF A NEW EUROPEAN PATENT FOR PROTECTING THE USE OF MASITINIB IN PANCREATIC CANCER PATIENTS.ANNOUNCES ISSUANCE OF A NEW EUROPEAN PATENT FOR PROTECTING USE OF MASITINIB IN PANCREATIC CANCER PATIENTS WITH PAIN UNTIL 2033.RECRUITMENT TARGET OF 330 PATIENTS IN ONGOING CONFIRMATORY PHASE 3 STUDY HAS JUST BEEN REACHED.  Full Article

Ab Science: CHMP adoptes negative opinion for masitinib in indolent systemic mastocytosis
Wednesday, 17 May 2017 

May 17 (Reuters) - AB SCIENCE SA ::REG-AB SCIENCE ANNOUNCES THAT CHMP HAS ADOPTED A NEGATIVE OPINION FOR MASITINIB IN INDOLENT SYSTEMIC MASTOCYTOSIS, PRIMARILY DUE TO GCP INSPECTION FINDINGS.AB SCIENCE WILL ASK FOR A RE-EXAMINATION WITH OPINION OF A SCIENTIFIC ADVISORY GROUP (SAG) TO EVALUATE BENEFIT-RISK BALANCE.HAS IMPLEMENTED THE CORRECTIVE ACTIONS TO ADDRESS THE GCP FINDINGS.AB SCIENCE WILL ASK FOR A RE-EXAMINATION.RE-EXAMINATION SHOULD LEAD THE CHMP TO DELIVER A SECOND OPINION IN Q4 2017.  Full Article

Trading resumption on shares of AB Science
Monday, 15 May 2017 

May 15 (Reuters) - Euronext::Announced today that trading on ordinary shares issued by AB Science <<>> will resume on Euronext Paris as of May 16, 2017 at 0900 CET.  Full Article

AB Science FY net loss widens to 27.7 million euros
Tuesday, 2 May 2017 

May 2 (Reuters) - AB Science SA ::Reported on Monday FY net revenues of 1.5 million euros ($1.64 million) versus 2.3 million euros a year ago.FY operating loss of 30.2 million euros versus loss of 26.0 million euros a year ago .FY net loss of 27.7 million euros versus loss of 26.7 million euros a year ago.In 2017 continues to allocate most of its resources to the development of masitinib, the most advanced molecule of the co.Following EMA filing of both registration dossiers in 2016 in severe systemic mastocytosis and amyotrophic lateral sclerosis, EMA decision should be known in May 2017 for systemic severe mastocytosis and during the fourth quarter of 2017 for amyotrophic lateral sclerosis.  Full Article

BRIEF-AB Science Presents New Preclinical Data For Masitinib In ALS

* ANNOUNCED ON TUESDAY NEW PRECLINICAL DATA FOR MASITINIB IN ALS AT 2019 MUSCULAR DYSTROPHY ASSOCIATION CONFERENCE